Literature DB >> 15316313

Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors.

Vikram Deshpande1, Carlos Fernandez-del Castillo, Alona Muzikansky, Anita Deshpande, Lawrence Zukerberg, Andrew L Warshaw, Gregory Y Lauwers.   

Abstract

The prediction of the behavior of pancreatic endocrine tumors (PETs) is a difficult exercise. CK19, a marker of pancreatic ductal cells, does not stain normal islet cells. Our aim was to evaluate the prognostic value of traditional parameters, including the Capella classification, as well as CK19. We evaluated the clinicopathologic features of 101 curatively resected PETs. The influence on survival of size, functional status of tumor, growth pattern, nuclear grade, mitoses (>2/10 HPF), vascular and perineural invasion, and necrosis was determined. Immunohistochemistry for Ki-67 and CK19 was performed in 45 and 54 cases, respectively. Cases were categorized as per the Capella classification as: benign, borderline, low-grade, and high-grade malignant. The different variables were tested by standard univariate and multivariate analyses. Mitoses (P = 0.03), solid pattern (P = 0.04), necrosis (P = 0.01), vascular invasion (P = 0.003), perineural invasion (P = 0.02), CK19 staining (P = 0.0008), and Ki-67 (P = 0.02) were significant prognostic indicators by univariate analysis while the Capella classification was not significant. By multivariate analysis, only CK19 was significant (P = 0.0008). None of the CK19-negative cases died of disease, while 10 of 28 CK19-positive cases died of disease and 3 are alive with disease. The Capella classification includes malignant tumors in its benign and borderline categories. CK19 is a powerful predictor of survival and can potentially segregate benign and malignant PETs. We suggest that all PETs with any one of the following features be diagnosed as malignant: presence of necrosis, vascular invasion, perineural invasion, or CK19 positivity. We hypothesize that a subgroup of PETs may share a common histogenesis with pancreatic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316313     DOI: 10.1097/01.pas.0000135525.11566.b4

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  21 in total

1.  Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.

Authors:  Zina Meriden; Chanjuan Shi; Barish H Edil; Trevor Ellison; Christopher L Wolfgang; Toby C Cornish; Richard D Schulick; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

Review 2.  Surgical management of pancreatic neuroendocrine tumors.

Authors:  Wataru Kimura; Koji Tezuka; Ichiro Hirai
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

Review 3.  Ectopic duodenal insulinoma: a very rare and challenging tumor type. Description of a case and review of the literature.

Authors:  Stefano La Rosa; Dario Pariani; Calogera Calandra; Alessandro Marando; Fausto Sessa; Ferdinando Cortese; Carlo Capella
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

Review 4.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

5.  Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.

Authors:  Joo Young Kim; Sang Hwa Lee; Soyeon An; Sung Joo Kim; You-Na Sung; Ki-Byung Song; Dae Wook Hwang; Song Cheol Kim; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2018-04-18       Impact factor: 4.064

Review 6.  Neuroendocrine tumors of the pancreas: current concepts and controversies.

Authors:  Michelle D Reid; Serdar Balci; Burcu Saka; N Volkan Adsay
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

7.  Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital.

Authors:  Mehrdad Nikfarjam; Andrew L Warshaw; Lloyd Axelrod; Vikram Deshpande; Sarah P Thayer; Cristina R Ferrone; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

Review 8.  Keratin expression in endocrine organs and their neoplasms.

Authors:  Peiguo G Chu; Sean K Lau; Lawrence M Weiss
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.

Authors:  Xu Han; Jing Zhao; Yuan Ji; Xuefeng Xu; Wenhui Lou
Journal:  Tumour Biol       Date:  2013-05-19

Review 10.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.